A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples